On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

Part of paid clinical trials in San Francisco, California.

Sponsor
Tennessee Retina
Study ID
NCT01670162
Phase
PHASE4
Status
Unknown

Conditions

  • Age Related Macular Degeneration
  • Pigment Epithelial Detachment

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept — DRUG
    Intravitreal Injection 2mg/0.05mL Aflibercept

Study Details

The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.

Key Dates

Start date
Aug 31, 2012
Status verified
Oct 2014
Primary completion
Nov 30, 2015
Completion
Jan 31, 2016

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 3 loading doses, then every 2 months
    All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.

Primary Outcome Measure

Proportion of patients with flattening of PED [ Time Frame: 12 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Pacific Eye AssociatesSan FranciscoCalifornia94115-
Retina Associates of KentuckyLexingtonKentucky40509-
Tennessee Retina, P.C.NashvilleTennessee37203-

Find similar trials in San Francisco, CA

By research site
Pacific Eye Associates· San Francisco, CARetina Associates of Kentucky· Lexington, KYTennessee Retina, P.C.· Nashville, TN

Related Studies